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Community-acquired pneumonia (CAP) is a common disease and a frequent cause of
morbidity and mortality worldwide. It puts an enormous burden on medical and economic
resources, particularly if hospitalization is required. Initial antibacterial therapy for CAP is
usually empirical, as culture and antibacterial sensitivity test results are rarely available at
initial diagnosis. Any agent selected for empirical therapy should have good activity
against the pathogens commonly associated with CAP, a favorable tolerability profile, and
be administered in a simple dosage regimen for good compliance. Streptococcus
pneumoniae remains the most common causative pathogen, although the incidence of
this organism varies widely. Streptococcus pneumoniae strains with decreased suscept-
ibility to penicillin have become increasingly prevalent over the past 30 years and are now
a serious problem worldwide. In addition, an increase in the prevalence of pneumococci
resistant to macrolides has been observed in Europe over recent years. Mycoplasma
pneumoniae and Chlamydia pneumoniae are among the most common atypical pathogens
isolated from patients with CAP. Haemophilus influenzae, Staphylococcus aureus and
Moraxella catarrhalis are less commonly identified as causative organisms. The emergence
and spread of resistance to commonly used antibiotics has challenged the management of
CAP. Multiple sets of CAP guidelines have been published to address the continued changes
in this complex disease.
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The management of adults with community-acquired pneu-
monia (CAP) remains a considerable challenge.1 CAP con-
tinues to be an important disease because of its frequency,
which is highest among the very young and the very old, and
its associated significant morbidity and mortality. CAP puts
an enormous strain on health-care resources, for example,
in the United Kingdom the annual cost has been calculated
to be4400 million [pounds sterling],2 and in Spain, the cost
of hospitalizations alone due to CAP was estimated at $137
million (in US dollars) per annum in 2001.3 Depending on the
severity of illness, CAP may be managed in either the
ambulatory or hospital setting. In a recent ISOCAP study in
Italy, the majority of 737 patients presenting to GPs with
CAP, were managed as outpatients, with only 8.5% requiring
hospitalization, due to age, co-morbidities or severity of
CAP.4 Similarly, in France, only 13 of 130 patients (10%) were
hospitalized initially, although a further 9 patients were
subsequently hospitalized due to treatment failure [diag-
nostic error (6) and antibiotic failure (3)].5
A number of factors influence a patient’s susceptibility to
specific pathogens in CAP, including age, disease severity at
presentation, co-morbidities (including immune status), site
of care (inpatient or outpatient), geographic location, and
local susceptibility patterns, including local trends with
respect to the incidence of drug-resistant Streptococcus
pneumoniae (DRSP), or other unusual pathogens.1
A variety of pathogens are known to cause CAP, yet, in
most patients with CAP (about 98% of those treated as
outpatients and 50%–60% of those treated as inpatients), the
causative organism is not known.6 Even in studies at
academic centers where every effort is made to cultureTable 1 Frequency of causative CAP organisms (%).
Organism Com
No pathogen identified 49.
Streptococcus pneumoniae 19.
Haemophilus influenzae 3.
Legionella spp 1.
Staphylococcus aureus 0.
Moraxella catarrhalis 0.
Gram-negative enteric bacteria 0.
Mycoplasma pneumoniae 11.
Chlamydiophila (Chlamydia) pneumoniae 8
Chlamydiophila (Chlamydia) psittaci 1.
Coxiella burnetii 0.
Adapted from Woodhead.10samples, the success rate in determining the microbiological
cause is usually about 50%.6 Given this diagnostic limitation,
clinicians must rely heavily on empiric antibiotic therapy.1
The prompt initiation of appropriate antibiotic therapy has
been shown to be essential for a favorable outcome.7Causative pathogens
Streptococcus pneumoniae is the most frequently isolated
organism from the outpatient, hospitalized and ICU setting
(see Table 1).8,9 Of the other causative agents, Stapylococ-
cus aureus, Legionella spp. and Gram-negative enteric
bacteria are uncommon in CAP that is managed outside
the hospital setting. These organisms appear with greater
frequency among patients with more severe disease and
rarely in those with mild illness, such as is generally
managed in the community. For Mycoplasma pneumoniae
the converse is true, with rising frequency as illness severity
decreases.10 M. pneumoniae, Legionella spp., Chlamydia
pneumoniae and respiratory viruses constitute the ‘‘atypi-
cal’’ pneumonia pathogens and with the exception of
Legionella spp. are causes of CAP, especially in outpatients.
Legionella spp. appears to vary in importance in different
countries.11,12 It appears to be more prevalent in Mediter-
ranean countries,12 and is uncommon in Northern European
countries.
Some patients with CAP may have a mixed infection
involving both ‘‘typical’’ and ‘‘atypical’’ pathogens,1
although the incidence of such co-infection is particularly
difficult to ascertain because the identification of atypical
pathogens in patients with CAP is usually made by serologic
testing, which only indicates whether there has beenmunity Hospital ICU
8 43.8 41.5
3 25.9 21.7
3 4.0 5.1
9 4.9 7.9
2 1.4 7.6
5 2.5 —
4 2.7 7.5
1 7.5 2
7 —
5 1.9 1.3
9 0.8 0.2
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Figure 1 Streptococcus pneumoniae resistance in Europe:
percentage of isolates non-susceptible to penicillin. Adapted
from Bruinsma et al.20
H.M. Lode1866exposure to these organisms and an immunologic response;
it does not necessarily establish that they are causative
agents of the pneumonia.6,13
Risks for CAP infection from other bacterial causes include
non-typeable Haemophilus influenzae and Moraxella catar-
rhalis (underlying bronchopulmonary disease), Enterobac-
teriaceae and Pseudomonas aeruginosa (chronic steroid
administration, severe underlying bronchopulmonary dis-
ease, carcinoma, diabetes mellitus, alcoholism, frequent
previous antimicrobial therapy), and anaerobes (aspiration
pneumonia, concomitant gingival disease, esophageal moti-
lity disorder).1 Risk factors for infection with drug resistant
strains of Streptococcus pneumoniae which have emerged
include age 465 years, previous b-lactam therapy (in last 3
months) and fluoroquinolone therapy, alcoholism, co-mor-
bidities and immunosuppressive illness or therapy. Staphy-
lococcus aureus CAP is associated with periods of high
influenza activity, and in communities with a high pre-
valence, MRSA may be causative of severe pneumonia.14
Staphylococcus aureus CAP is otherwise most often seen in
ICU patients, with risk factors including end stage renal
failure, injection drug abuse and prior antibiotic therapy,
especially with fluoroquinolones and post viral influenza.
Severe pneumonia with necrotizing features has been
documented in Europe caused by Panton Valentine leukoci-
din -producing CA-MRSA.15,16
Other less common causes of CAP include Mycobacterium
tuberculosis, Francisella tularensis, Bordetella pertussis,
Streptococcus pyogenes, Neisseria meningitidis, Pasteurella
multocida, Chlamydia psittaci, H. influenzae type b and
endemic fungi. Coxiella burnetii is a rare cause of CAP;
however, there appears to be some geographic variation in
the frequency with which this organism is isolated. It is
virtually non-existent in some parts of Scandinavia,11 yet it
is the second leading cause of CAP, second only to
Streptococcus pneumoniae, in northwest Spain.17Antibiotic resistance and CAP
The relatively recent development of resistance among CAP
pathogens to antibiotics once routinely effective against
these organisms has prompted modifications in the manage-
ment of CAP. Further, because infections caused by resistant
pathogens are associated with higher morbidity and mortal-
ity than those caused by susceptible pathogens, the global
impact of increasing resistance is a major concern.18,19 The
frequency of resistance varies markedly between European
countries. Because Streptococcus pneumoniae predomi-
nates as the causative CAP pathogen, considerable effort
has been put into tracking the emergence of resistant
pneumococcal isolates.
Data for isolates collected over a five-year period
(1999–2004) by the European Antimicrobial Resistance
Surveillance System (EARSS) show levels of penicillin non-
susceptibility amongst Streptococcus pneumoniae ranging
from o5% to 440% (Fig. 1).20 It is encouraging to note that
the data show a decrease in penicillin non-susceptibility in
four countries (from 13% to 9% in Belgium, from 19% to 10%
in Ireland, from 7% to 3% in the UK and from 33% in 2000 to
29% in Spain), which may be attributable to the uptake of
pneumococcal vaccination programmes.21Similar resistance problems have surfaced with respect to
macrolide resistance. The EARSS data indicate that Spain
and Belgium have the highest rates of macrolide-resistant
Streptococcus pneumoniae isolates. However, other surveil-
lance studies suggest that macrolide resistance is also an
increasing problem in France.22 The development and
widespread availability of the ‘‘respiratory’’ fluoroquinolone
antibiotics with enhanced activity against Streptococcus
pneumoniae, compared to ciprofloxacin and ofloxacin, has,
predictably, been followed by reports of resistance to these
agents also.23 This emergence of drug-resistant pneumo-
coccal infections has caused considerable concern among
physicians treating these infections.24 Because the resis-
tance to b-lactam agents and macrolides in many pneumo-
coccal strains is low level, with MICs only slightly above
Clinical Laboratory Standards Institute (CLSI, formerly
NCCLS: http://www.nccls.org) breakpoints, the clinical
importance of this resistance has been questioned.25–27
Indeed, at least one study of the molecular epidemiology of
Streptococcus pneumoniae has shown that penicillin resis-
tance is not a risk factor for fatal disease.28 Because
resistance was not a risk factor, the authors concluded that
resistance in pneumococcal strains may actually reduce
virulence, perhaps by causing the bacteria to grow more
slowly relative to the wild type and thus reducing the ability
of the resistant strain to survive and cause disease.
The clinical relevance of macrolide resistance in Strepto-
coccus pneumoniae isolates has similarly been questioned.29
Treatment failures for macrolide therapy of pneumococcal
infections have been rare despite the increasing resistance
to these agents. The level of resistance to date has been
relatively low, which may explain the success of macrolide
therapy despite the presence of resistance. Another
explanation may be that these resistant strains are more
easily treated due to a loss of virulence, as has been shown
experimentally with penicillin-resistant strains. However, an
increase in the level of macrolide resistance in pneumococci
together with mutations that restore virulence are likely to
evolve and create clinically troubling resistant pneumococ-
cal strains. Yu et al.30 performed a prospective study of 844
hospitalized patients with blood cultures positive for
Streptococcus pneumoniae and found that 15% of these
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(minimum inhibitory concentration [MIC], 0.12–1mg/mL),
and 9.6% were resistant (MIC, X2 mg/mL). They further
found that while age, severity of illness, and underlying
disease with immunosuppression were significantly asso-
ciated with mortality; penicillin resistance was not a risk
factor for mortality. Assessment of the impact of concordant
antibiotic therapy (i.e., receipt of a single antibiotic with in
vitro activity against Streptococcus pneumoniae) versus
discordant therapy (inactive in vitro) on mortality showed
that discordant therapy with penicillins, cefotaxime, and
ceftriaxone (but not cefuroxime) did not result in a higher
mortality rate. Similarly, time required for defervescence
and frequency of suppurative complications were not
associated with concordance of b-lactam antibiotic therapy.
The authors concluded that b-lactam antibiotics should be
used to treat pneumococcal infections that do not involve
cerebrospinal fluid, regardless of in vitro susceptibility.30
Antibiotic resistance impacts each country to a different
degree, but there does appear to be a consensus that
resistance is an inevitable consequence of inappropriate
antibiotic use. Thus, until prescribing habits are modified in
those regions where antibiotic resistance is growing, it will
continue to be a problem. Physicians should make use of
local susceptibility data to make informed decisions with
respect to their antibiotic prescribing and use.Guidelines
Guidelines help physicians to stratify patients according to
specific risk factors, and provide diagnostic and treatment
options for patients in the community, hospital or intensive
care units. Several studies have shown that implementation
of CAP guidelines results in a significant reduction in
morbidity and mortality.31–33 Moreover, a study by Marrie
et al.34 showed that following CAP guidelines allowed
physicians to safely identify patients that could be treated
as outpatients, resulting in decreased hospitalization rates,
which in turn would lead to a decreased length of hospital
stay, with a concomitant decrease in the cost of care.
The most recent European CAP guidelines (2005) recom-
mend that a patient should be suspected of having
pneumonia when acute cough, and one of the following
signs/symptoms are present: new focal chest signs, dyspnea,
tachypnea, fever lasting 44 days with diagnosis confirmed
by chest radiograph.35 CAP is often managed in the
outpatient setting. However, many patients are hospitalized
who could be treated as outpatients, increasing hospital
costs and the patient’s risk of death, thromboembolic events
and superinfection with resistant nosocomial bacteria. Both
US (2007) and European guidelines recommend that an
initial assessment of CAP severity is carried out using
objective criteria [CURB (Europe) and CURB-65 (US) criteria
and/or the Pneumonia Severity Index (PSI)] which, together
with other factors, including patient ability to reliably take
oral therapy and the availability of outpatient support, may
aid the identification of patients appropriate for outpatient
or inpatient care.1,35
The main determinants of the PSI are increasing age; co-
morbidity; vital sign, laboratory and radiographic abnorm-
alities; oxygenation parameters and nursing home residency.Patients are stratified into 5 mortality risk classes; I–III
(mortality risk up to 3%), IV (8%) and V (35%). European
guidelines suggest that patients in class IV and V should be
seriously considered for hospitalization. US guidelines
suggest treatment as an outpatient for classes I and II; in
an observation unit or with short hospitalization (class III); or
as inpatients (classes IV–V). The CURB index, in European
guidelines, is an acronym for 4 variables: mental confusion,
blood urea nitrogen (BUN) level47mmol L1, Respiratory
rateX30min1, and diastolic Blood pressure of 60mmHg.
The presence of each criteria scores 1 point. Patients with a
CURB score 0 have a risk mortality of 1%, 1–2 (8%), 3–4
(30%). Patients with a CURB score of X2 should be seriously
considered for hospitalization. In US guidelines, the CURB-65
criteria has been extended to include age X65 years.
Patients with CURB-65 scores of 0–1 are treated as out-
patients, X2, hospitalization or intensive in home health
care, and 43, ICU care is often required.
Both European and US guidelines suggest that it is unsafe
to rely on PSI or CURB score alone for determination of
hospitalization. Studies have shown that some patients with
low PSI or CURB-65 scores require hospital admission, even
to ICU. Other factors for hospitalization of low-mortality risk
patients include supplemental oxygen requirement, pleural
effusion drainage, CAP complications, underlying disease
exacerbation, inability to reliably take oral medication or
receive outpatient care, and/or multiple risk factors falling
just above/below score thresholds. Increasing age as a
major determinant in the PSI, may lead to underestimation
of pneumonia in younger patients. The CURB criteria based
on pneumonia severity, avoids this problem and potential
bias from co-morbidities. It is also easier to calculate the
score for CURB, as opposed to the PSI with 20 variables and
complex scoring.
European guidelines suggest that once a decision has been
made to treat as an outpatient, clinical reassessment should
be carried out in 24–48 h, as deterioration is most likely to
occur during this time. Hospitalization of patients initially
treated as outpatients is infrequent (7.5%) within 10 days,
but they are at a greater risk of death, and longer recovery
time. European guidelines suggest that if there is any doubt,
hospitalize.35
Criteria for admission to ICU describe patients at
increased risk of death. In European guidelines, PSI and
CURB criteria have not been used to predict severe
pneumonia in individual patients and may be of limited
value.35 In US guidelines, direct admission to ICU is required
for patients with 2 major criteria of septic shock requiring
vasopressors and acute respiratory failure requiring intuba-
tion and mechanical ventilation.1 Direct admission to ICU or
high-level monitoring unit is recommended for patients with
3 minor criteria including respiratory rate (X30 breaths/
min), PaO2/FiO2 ratiop250, multilobar infiltrates, confu-
sion/disorientation, uremia, leukopenia, thrombocytopenia,
hypothermia or hypotension requiring aggressive fluid
resuscitation. In European guidelines, referral to ICU in all
unstable patients should be guided by the presence of X2
indicators of severe pneumonia; systolic blood pressure
o90mmHg, severe respiratory failure (PaO2/FiO2 ra-
tiop250), multilobar involvement or a requirement for
either mechanical ventilation or vasopressors 44 h (septic
shock).35
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between those issued in North America and those released
in Europe. The two approaches differ primarily because of
the greater emphasis in North America to routinely treat the
atypical pathogens and the fact that macrolide-resistance to
Streptococcus pneumoniae is of a higher level in Europe than
in North America because of the difference in resistance
mechanisms between North America (mef) and Europe
(erm). The risk of pneumococcal infections increases
linearly with age, disability and hospitalization.35 A higher
frequency of gram-negative enteric bacteria (GNEB), Sta-
phylococcus aureus, P. aeruginosa and anaerobic pathogens
is also reported in elderly and institutionalized patients.36
The North American approach is to use broad initial
coverage, whereas Europeans focus on providing pneumo-
coccal coverage with less emphasis on covering atypical
pathogens. While the role of atypical pathogens in CAP
appears to be established among North American investiga-
tors, their importance in Europe continues to be debated,
partly due to diagnostic difficulties. Disease caused by M.
pneumoniae or C. pneumoniae is thought frequently to be
self-limiting, and many investigators feel that initial
empirical coverage against these pathogens is unnecessary.
However, in patients hospitalized with CAP, current guide-
lines recommend empiric therapy which includes atypical
coverage.37
Current US guidelines recommend macrolides, doxycy-
cline, a respiratory fluoroquinolone or the combination of a
b-lactam plus macrolide as treatment options for individuals
who can be treated as outpatients.1,38 In general, the North
American guidelines recommend a macrolide as first-line
treatment for outpatients with no co-morbidity or risk
factors for drug-resistant Streptococcus pneumoniae.
Macrolides are considered in North America to provide
effective therapy for Streptococcus pneumoniae and for the
atypical organisms, such as M. pneumoniae and C. pneumo-
niae, which are relatively common in outpatients. In
contrast, the British Thoracic Society guidelines recom-
mended b-lactams, primarily penicillins as first-line ther-
apy.39 The rationale here is that these agents are effective
against Streptococcus pneumoniae, even strains with de-
creased sensitivity to penicillin if the antibiotics are given atTable 2 Summary of antibiotic recommendations for CAP from
Setting Severity/subtype Treatment
Recommended
Outpatient All Amoxicillin or tet
Hospital Nonsevere Penicillin G7mac
Aminopenicillin7
amoxiclav7macr
cephalosporin7m
Hospital Severe 3rd Cephalospori
Hospital Severe and risk factors for
Pseudomonas aeruginosa
Anti-pseudomona
cephalosporin+cipa high enough dose. The guidelines suggest that because M.
pneumoniae exhibits epidemic periodicity every 4–5 years
and largely affects younger patients, initial empirical
therapy that aims to cover this pathogen is unnecessary.
The British guidelines thus place less significance than their
North American counterparts on the need to treat empiri-
cally outpatients who are infected with atypical pathogens.
In hospitalized patients, a recently published systematic
review of CAP admissions covering an eight year period
reported that empirical antibiotic coverage of atypical
pathogens did not reduce mortality or improve clinical
efficacy.40
Current European guidelines provide recommendations
for the diagnosis and treatment of the three most common
lower respiratory tract infections: CAP, acute exacerbations
of chronic obstructive pulmonary disease (COPD; AECB) and
exacerbations of bronchiectasis. Unlike previous guidelines,
ERS/ESCMID guidelines are presented in a question and
answer format. They ask the following key questions: how
do I diagnose or identify CAP?; how should I treat my patient
with CAP?; and how should I prevent CAP? They do not
recommend outpatient testing for the etiologic cause of the
infection; rather, their recommendations for antimicrobial
therapy are based on the severity of illness; the frequency of
specific pathogens; local patterns of microbial resistance;
and drug safety profiles (see Table 2). These guidelines also
emphasize the probability of a viral cause for the pneumo-
nia, and in so doing remind physicians of the importance of
withholding antibiotics to reduce costs and simultaneously
minimize the emergence of antibiotic-resistant bacterial
strains in the community.
Initial treatment should be empiric according to risk of
mortality related to pneumonia severity distinguishing low
risk patients treated as outpatients (mild pneumonia);
patients at increased risk and hospitalized (moderate
pneumonia) and patients with a high risk admitted to ICU
(severe pneumonia.). Antimicrobial therapy should be rapid
(within first 2 h of hospitalization or within first hour after
ICU admission) and appropriate to the general pattern of
expected pathogens according to pneumonia severity and
additional risks factors. [In hospitalized patients, Strepto-
coccus pneumoniae is the most frequent pathogen, and thusthe European CAP guidelines by Woodhead et al.35
Alternative
racycline. Co-amoxiclav, macrolide,
levofloxacin, moxifloxacin
rolide;
macrolide; Co-
olide; 2nd or 3rd
acrolide
Levofloxacin, moxifloxacin
n+macrolide 3rd Cephalosporin+(levofloxacin or
moxifloxacin)
l
rofloxacin
Acylureidopenpenicillin/b-lactamase
inhibitor+ciprofloxacin or
Carbapenem+ciprofloxacin
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frequency of others is dependant on population, age/region,
season but are most commonly H. influenzae, M. pneumo-
niae, C. pneumoniae. In ICU there is the potential for higher
frequency of Legionella spp., GNEB, P. aeruginosa but not so
much H. influenzae and M. pneumoniae. For GNEB/P.
aeruginosa there is considerable variability in incidence
across Europe with regional and local patterns of microbial
resistance [penicillin resistance is 50% in France and Spain,
Germany (5%)].41 Recommended preferred treatment op-
tions for hospitalized patients with CAP in regions with low
resistance rates include; either penicillin G, aminopenicil-
lin, aminopenicillin/b-lactamase inhibitor or non-antipseu-
domonal cephalosporin II or III; each7a macrolide (new
macrolide preferred to erythromycin). In regions with
increased resistance rates or intolerance to preferred
drugs, levofloxacin or moxifloxacin may be alternatives.
When oral treatment is adequate, ketolides may offer an
alternative. In patients with severe CAP, and no risk factors
for P. aeruginosa, guidelines recommend a non-antipseudo-
monal cephalosporin III+a macrolide or moxifloxacin or
levofloxacin and with risk factors for P. aeruginosa, either
an antipseudomonal cephalosporin, aclyureidopenicillin/
b-lactamase inhibitor or a carbapenem; each with cipro-
floxacin. Guidelines also list recommended treatment for
specific pathogens, including intermediate and highly
resistant Streptococcus pneumoniae, MSSA, MRSA.
Oral therapy is appropriate for hospitalized, mild CAP and
for all patients treated in the community. In hospitalized
patients not requiring ICU admission, European guidelines
support the consideration of sequential treatment unless
there are contraindications (impaired gastrointestinal ab-
sorption, inability to swallow oral medication due to
impaired consciousness). Resolution of the most prominent
clinical feature at admission may be used as the signal to
switch from IV to oral therapy. Intravenous therapy needs
only be instituted in patients with severe CAP. For patients
treated in the community, antibiotic monotherapy is
directed against Streptococcus pneumoniae. Empirical anti-
biotic therapy for hospitalized patients varies according to
the severity of the pneumonia. In non-severe cases, where
pneumonia is the cause of admission, combination oral
therapy is recommended because of the greater incidence
of atypical pathogens. In severe CAP, combination intrave-
nous therapy using a broad-spectrum b-lactam antibiotic
plus a macrolide should be commenced immediately. The
guidelines recommend the use of a fluoroquinolone with
gram-positive coverage for patients intolerant of penicillins
and macrolides.
US CAP guidelines suggest that there is substantial overlap
among patients with CAP and patients with healthcare-
associated pneumonia (HCAP) for whom separate guidelines
have been published.42 However, it is suggested that some
patients with HCAP with specific pathogens may be better
managed under CAP guidelines. HCAP is associated with
patients who have close association with acute care
hospitals or reside in chronic care settings (nursing home
and other long term care facilities) that increase their risk of
pneumonia caused by MDR bacteria such as MRSA, Gram-
negative bacilli (P. aeruginosa, ESBL Klebsiella pneumoniae
and Acinetobacter spp.). European guidelines do not
mention HCAP. However, in a recent Spanish study investi-gators concluded that healthcare-associated pneumonia
should be regarded as a separate entity to CAP with a
distinct approach to antimicrobial therapy.43 Of 389 patients
admitted to hospital with CAP, 20% were HCAP. Patients with
HCAP were older, had more co-morbid conditions, and were
more commonly assessed as high severity risk classes than
CAP patients. Aspiration and Gram-negative pneumonia
were more frequent, whereas Legionella spp. and atypical
bacteria were rarely identified. Mortality was higher in HCAP
patients (8%) compared to CAP (3%).Prevention of CAP
Vaccines targeting pneumococcal disease and influenza are
important in the prevention of CAP. In a recent worldwide
meta-analysis, in homes for the elderly, well matched IM
inactivated influenza vaccine prevented pneumonia with a
vaccine efficacy of 46%, but in the elderly living in the
community, it was not significantly effective (Relative risk,
RR, 0.88, 0.64–1.20).44 However, influenza vaccination has
been shown to be effective (adjusted odds ratio 0.21 and
33%, respectively) in reducing hospital admissions due to
pneumonia in non-institutionalized older adultsX65 years in
Spain and in Italy.45,46 European guidelines suggest inacti-
vated influenza vaccine should be given annually to persons
with increased risk of complications due to influenza
including immunocompromised adults aged X65 years;
institutionalized, or with chronic cardiac, pulmonary or
renal disease, diabetes mellitus, and/or hemoglobinopa-
thies; females who will be in the 2nd or 3rd trimester of
pregnancy in the influenza season; health care personnel or
persons in contact with high risk patients. US guidelines
recommend inactivated influenza vaccine for all persons
450 years, younger persons (6 months–49 years) in high risk
groups, household contacts of high risk persons and health
workers. The inactivated rather than the intranasal spray
live attenuated vaccine, is recommended in adults in the
European guidelines, however, in US guidelines the live
vaccine is recommended for healthy persons 5–49 years,
including health care workers.
The evidence for the effectiveness of IM 23-valent
pneumococcal polysaccharide vaccine (PPV) in prevention
of pneumonia is not as strong as for influenza vaccination.
However, in a recent Spanish study (EVAN-65), the 23-valent
PPV was significantly effective (45%) in preventing pneumo-
coccal pneumonia and was associated with a significant
reduction in the risk of hospitalization for pneumonia
(hazard ratio, HR 0.74), the overall pneumonia rate (HR
0.79) and in the risk of death (59%) in vaccinated individuals
of mortality due to pneumonia in older non-institutionalized
adults (X65 years).47. European guidelines recommend that
PPV is given to all adults at risk from pneumococcal disease
including X65 years, institutionalized, with dementia,
seizure disorders, congestive heart failure, cerebrovascular
disease, COPD, history of previous pneumonia, chronic
liver disease, diabetes mellitus, asplenia, chronic cerebro-
spinal leakage. In US guidelines, IM pneumococcal poly-
saccharide vaccine (PPV) is recommended for all older
persons (X65 years) and high-risk younger persons
(2–64 years). Smokers are included in US, but not European
guidelines.
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As previously stated, CAP is associated with significant
morbidity, mortality and utilization of health care re-
sources. Strategies for decreasing the cost of treating CAP
include identifying low-risk patients who can safely be
treated as outpatients, decreasing lengths of hospital stay,
decreasing the use of emergency departments as sites for
initial evaluation, and promoting the use of lower cost
antibiotic therapy. Stratification of CAP severity is mostly
based on the Fine criteria in the United States and on the
CURB-65 criteria in Europe.48,49
In the US, hospitalization costs resulting from CAP have
been estimated to be between US$7000 and US$8000 per
admission or US$4 million per 100,000 individuals. In Europe,
hospitalization costs are significant (representing about
90% of the total costs), but are much lower than in the
US (one-third to one-ninth of the US estimates in the UK
and Spain, respectively). A review of US and European
economic studies of the treatment of CAP by De Graeve
and Beutels50 suggests that, in general, these studies are in
line with clinical evidence. A drug with proven clinical
effectiveness appears to be supported from an eco-
nomic standpoint. Economic data also support an early
switch from an intravenous to an oral antibacterial, the
use of fluoroquinolones for inpatients with CAP, and the
use of guidelines built on clinical evidence. However,
Barlow et al recently evaluated the effect of implemen-
ting the British Thoracic Society CAP guidelines on anti-
biotic prescribing and costs in a UK teaching hospital and
found an increase in antibiotic use and, therefore costs.51
Overall, broad-spectrum antibiotic prescribing increased
from 42.5% to 77.5% at the intervention site, but decreased
from 45% to 41.5% at the control site. There were no
significant differences or trends towards improvement in
length of hospital stay or 30-day mortality rates. Before
implementation, the mean cost of the first dose of
antibiotic(s) prescribed was £6.34 (Euro 8.9) at the inter-
vention site and £4.83 (Euro 6.8) at the control site. Post-
implementation, costs increased at both sites to £9.01 (Euro
12.6) at the intervention site and £6.42 (Euro 9.0) at the
control site.51
The results of the cost-effectiveness studies of influenza
vaccination in healthy adults have varied. One study
demonstrated a net cost of US$68.00 per vaccinated subject
in a year with a poor match between vaccine and infecting
strains compared to US$11.00 during the following year with
a good vaccine match.44 Other studies have found cost
savings with vaccination, particularly in long-term health-
care facilities. In elderly persons, vaccination is probably
cost-effective relative to providing anti-viral treatment with
neuraminidase inhibitors.
The pneumococcal polysaccharide vaccine appears to be
relatively cost effective (and potentially cost saving) for
those between 65 and 75 years of age, for military recruits
and for HIV positive patients with a sufficiently high CD4 cell
count.50 Evaluations of the pneumococcal conjugate vaccine
(PCV) indicate that the price of the vaccine is the main
determinant of cost effectiveness, but this vaccine has an
impressive impact on the frequency of pneumococcal
pneumonia, pneumococcal colonization, and resistance
development.52New antibiotic options for the treatment
of CAP
Ceftobiprole medocaril is a broad spectrum IV cephalosporin
with excellent activity against penicillin-resistant pneumo-
cocci and MRSA, VRSA, ampicillin-sensitve enterococci, b-
lactamase positive H. influenzae and M. catarrhalis.53 It has
a favorable pharmacokinetic and safety profile and may be a
promising antimicrobial for the treatment of CAP in patients
requiring hospitalization. However, it has not demonstrated
any activity against ESBL-producing Enterobacteriaceae
which may limit its clinical usefulness.
Quinupristin-dalfopristin is a IV semi-synthetic strepto-
gramin, and has activity against serious Gram-positive
pathogens including penicillin resistant Streptococcus pneu-
moniae, MRSA and ERSA.54 However, it should not be used in
the treatment of nosocomial MRSA as it has been shown to
be inferior in clinical trials.55 It also is not active against the
majority of Gram-negative bacilli or Pseudomonas aerugi-
nosa.
The lipopeptide, daptomycin failed to meet statistical
noninferiority criteria in an in vitro modeling trial.56 It was
shown to interact with pulmonary surfactant, resulting in
inhibition of antibacterial activity; it was efficacious to
Staphylococcus aureus heamatogenous pneumonia, but
demonstrated no activity against Streptococcus pneumoniae
in simple bronchial alveolar pneumonia.
The oxazalidinone linezolid shows activity against Gram-
positive CA-MRSA, GISA, and multidrug-resistant Strepto-
coccus pneumoniae. It can be administered i.v. in serious
infections or orally in less serious conditions. In pooled
clinical studies of CAP due to MDRSP, clinical efficacy was
73%.57 Recent data suggest that linezolid may also be
considered in the treatment of MRSA nosocomial pneumonia
in patients with vancomycin-induced nephrotoxicity or
documented lack of response to vancomycin.55 Adverse
events with prolonged linezolid use include thrombocyto-
penia and serotonin syndrome.
Telithromycin, is a first in class oral ketolide. Its main
advantage is its enhanced activity against macrolide-
sensitive and resistant Streptococcus pneumoniae. Against
atypical bacteria, it has similar or slightly greater activity
than macrolides. It has been shown to be an effective new
option in the treatment of CAP.58 However, Enterobacter-
iaceae are intrinsically resistant to macrolides and keto-
lides. There have been several reports of serious liver
toxicity, loss of consciousness and visual disturbances
following telithromycin administration and contraindica-
tions in myasthenia gravis leading to a change of label in the
United States restricting its use to the treatment of CAP.59
One of the newest respiratory fluoroquinolones, oral
gemifloxacin has enhanced activity against Gram-positive
cocci, and is the most potent fluoroquinolone against drug
resistant Streptococcus pneumoniae including penicillin-,
macrolide- and many ciprofloxacin-resistant strains.60 It is
the least likely of the fluoroquinolones to be affected by
resistance, and has the most impressive pharmacokinetic
profile. A frequent adverse event of mild rash has been
recorded in younger women, which may limit its clinical
utility. Current evidence supports the use of respiratory
fluoroquinolones as first choice agents in CAP, however
increasing resistance may threaten the class.
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currently undergoing clinical evaluation as a therapeutic
option for the treatment of CAP, especially in countries with
high rates of multi-drug resistant Streptococcus pneumo-
niae. The in vitro activity of tigecycline has been shown to
cover many community-acquired pathogens.61,62 Tigecycline
may provide clinicians with an expanded spectrum antibiotic
option that can be used at the onset of treatment when the
specific bacteria present are not yet known. In a recent
Phase III study it was demonstrated that tigecycline was
slightly more clinically effective (88.9%) than levofloxacin
(85.3%) in the treatment of hospitalized patients with
CAP.63 For patients with a Fine score of o3 or 3/4, clinical
efficacy for tigecycline was 89.6% and 88.0%, respectively,
and for levofloxacin was 87.3% and 83.3%, respectively.
Adverse events of nausea (26.9% tigecycline vs. 8.5%
levofloxacin), vomiting (16.7% vs. 6.6%,) and leucocytosis
(6.9% vs. 0.9%,) were more common in tigecycline-treated
patients, whereas hypokalemia was more common in
levofloxacin treated patients (0.5% tigecycline vs. 3.8%
levofloxacin, P ¼ 0.019). Further studies will provide more
information on the clinical utility of tigecycline, which may
be of therapeutic significance to treat multi-drug resistant
pneumococci.Conclusion
Community-acquired pneumonia (CAP) is a major global
public health problem, affecting millions of people annually.
Up to a third of patients are hospitalized with CAP, and this
infection contributes considerably to morbidity and mortal-
ity. Despite continuous advances in the diagnosis and
treatment of CAP, this infection remains a significant
socioeconomic burden, and its management presents a
challenge to physicians. The predominant pathogen asso-
ciated with CAP is Streptococcus pneumoniae; other
commonly identified pathogens include H. influenzae, and
atypical organisms, such as M. pneumoniae, C. pneumoniae
and Legionella spp. For years, Streptococcus pneumoniae
was sensitive to penicillin, and b-lactams were an effective
treatment option for Streptococcus pneumoniae infections.
However, over the past 20 years, drug-resistant pneumo-
cocci have spread rapidly over a wide geographic area, such
that today drug-resistant Streptococcus pneumoniae is
recognized worldwide. Surveillance programs developed to
track resistance to Streptococcus pneumoniae and other
organisms are currently reporting the prevalence of
Streptococcus pneumoniae non-susceptibility to penicillin
to be as high as 50% and the prevalence of resistance
to macrolides to be similarly on the rise. Of particular
concern is the increasing prevalence of resistance to
fluoroquinolones. Although fluoroquinolone-resistance has
been slow to emerge, there are now more and more
geographic regions reporting resistance. As resistance to
commonly prescribed antibiotics for CAP has increased, the
need for safe and effective new antimicrobials has grown, as
has the call for more judicious use of antibiotics. Updated
guidelines are of immense value to physicians trying to help
their patients overcome this still common, yet serious
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